Boston, MA 08/19/2014 (wallstreetpr) – CEL-SCI Corporation (NYSEMKT:CVM) said that it was taking ahead its Phase III Immunotherapy Neck and Head Cancer clinical trial into Centre Hospitalier Universitaire de Quebec based in Canada. The trial is of the investigational cancer immunotherapy treatment known as Multikine. It is expanding its clinical sites in North America. It wants to accelerate the patient enrollment in Canada.
The details
The Investigator for the Phase III trial is Dr. André Fortin. He will look after the investigation at CHUQ. He will monitor the research protocols of radiation therapy CHUQ. He has got extensive expertise and years of experience in treating cancers by the use of radiation therapy. He has treated various forms of cancers including head, neck, digestive and pulmonary cancers. He is an important part in clinical research within the oncology department.
The Phase III study
A Phase III study in respect of Multikine treatment is related with the head and neck cancer treatment. It enrolls only those patients who have advanced primary, but not yet treated form of head and neck cancer. The Phase III study is meant to show a statistically visible improvement in overall survival of patients who enrolled for Multikine treatment regimen, as well as Standard of Care vs. subjects, but treated with SOC only.. The treatment is meant to develop an anti-tumor immune response. The treatment will minimize the chances of the recurrence of the local or regional tumor. If the recurrence rate is reduced, it will enhance the survival rate of the patients who are victim of the neck and head cancer.
The objective
CEL-SCI Corporation (NYSEMKT:CVM) is adding up centers for Phase III trial in Canada and the US. It is the world’s largest clinical trial for head and neck cancer treatment. CEL-SCI Corporation wants to achieve the global enrollment target of around 880 patients by the end of year 2015.
